Results 21 to 30 of about 2,381,535 (223)

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.

PLoS ONE, 2020
BackgroundPakistan is among top five high burden countries for tuberculosis and drug resistant TB. Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is 8.3% (95%CI: 7.0-10.7) and resistance to fluoroquinolone is higher
Sabira Tahseen, Faisal Masood Khanzada, Alamdar Hussain Rizvi, Mahmood Qadir, Aisha Ghazal, Aurangzaib Quadir Baloch, Tehmina Mustafa   +6 more
doaj   +1 more source

Rifampicin resistance in tuberculosis outbreak, London, England [PDF]

, 2005
Mycobacterium tuberculosis isolates cultured from 6 patients associated with an isoniazid-resistant M. tuberculosis outbreak acquired rifampicin resistance. The rpoB gene sequence showed that resistance was associated with rare mutations in each isolate.
Shorten, R J, McHugh, TD, Claxton, A P, Claxton, AP, Mary Jo Knobloch, Gillespie, S H, Claire Jenkins, Stephen H. Gillespie, Shorten, RJ, McHugh, T D, Edward A. Belongia, Richard E. Besser, Timothy D. McHugh, Robert J. Shorten, Burney A. Kieke, Carolyn Janette, Gillespie, SH, Jeffrey P. Davis, Jenkins, C, Alleyna P. Claxton, Gillespie, S H ; id_orcid   +20 more
core   +1 more source

Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance

BMC Infectious Diseases, 2022
Background The UK has implemented routine use of whole genome sequencing (WGS) in TB diagnostics. The WHO recommends addition of a fluoroquinolone for isoniazid mono-resistance, so early detection may be of use.
Mirae Park, Ajit Lalvani, Giovanni Satta, Onn Min Kon   +3 more
doaj   +1 more source

Prevalence of genetic pattern in isoniazid-resistant PTB cases and its association with other TB-resistance drugs

Journal of Dr. NTR University of Health Sciences, 2022
Introduction: Isoniazid (H) is one of the most important first-line antituberculosis drugs used for the treatment of active tuberculosis (TB) and latent TB infection (LTBI) with high bactericidal activity and a good safety profile.
S. Lakshmi Kumari, Srikanti Raghu, Karri Maruthi Devi, Aswina Tripura Sundari, D. Sudheer, P. Hima Sanjana   +5 more
doaj   +1 more source

Drug resistance-conferring mutations in Mycobacterium tuberculosis from Madang, Papua New Guinea [PDF]

, 2012
: BACKGROUND: Monitoring drug resistance in Mycobacterium tuberculosis is essential to curb the spread of tuberculosis (TB). Unfortunately, drug susceptibility testing is currently not available in Papua New Guinea (PNG) and that impairs TB control in ...
Gagneux, S., Siba Peter, Beck, H. P., Hans-Peter Beck, Beck Hans-Peter, Carter Robyn, Paul Harino, Harino, P., Carter, R., Serej Ley, Ley Serej, Siba, P., Gagneux Sebastien, Borrell Sonia, Coscolla Mireia, Mireia Coscolla, Ballif Marie, Stefan Niemann, Ley, S., Marie Ballif, Coulter, C., Robyn Carter, Coulter Christopher, Christopher Coulter, Ballif, M., Peter Siba, Niemann, S., Harino Paul, Niemann Stefan, Sebastien Gagneux, Phuanukoonnon, S., Borrell, S., Coscolla, M., Sonia Borrell, Suparat Phuanukoonnon, Phuanukoonnon Suparat, Ballif M, Gagneux S, Harino P, Carter R, Borrell S, Coulter C, Niemann S, Beck HP, Phuanukoonnon S, Ley S, Siba P, Coscolla M   +47 more
core   +1 more source

Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. [PDF]

, 2010
OBJECTIVE: Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB). We describe characteristics of TB in individuals previously exposed
Grant, Alison D, van Halsema, Clare L, Churchyard, Gavin J, Fielding, Katherine L, Chihota, Violet N, Lewis, James JC, Russell, Elizabeth C   +6 more
core   +1 more source

Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. [PDF]

PLoS ONE, 2016
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on
Leonela Villegas, Larissa Otero, Timothy R Sterling, Moises A Huaman, Patrick Van der Stuyft, Eduardo Gotuzzo, Carlos Seas   +6 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

EXPERIENCE IN TREATMENT OF A PATIENT WITH ISONIAZIDE-RESISTANT PULMONARY TUBERCULOSIS

Актуальные проблемы теоретической и клинической медицины, 2022
Isoniazid-resistant tuberculosis (HR-TB) is characterized by resistance to isoniazid and sensitivity to rifampicin. This form can be viewed as a potential precursor to multidrug-resistant tuberculosis (MDR-TB).
G. A. Smailova, G. L. Sagintaeva
doaj   +1 more source

Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis

, 2020
The molecular basis for isoniazid resistance in Mycobacterium tuberculosis is complex. Putative isoniazid resistance mutations have been identified in katG, ahpC, inhA, kasA, and ndh.
Varma-Basil M., Cave M.D., Guerrero M.I., Fyfe J., Bose M., Billman-Jacobe H., Sifuentes-Osornio J., Lavender C., Brimacombe M., Del Valle M.B., León C.I., Alland D., Hazbón M.H., Cavatore M., De León A.P., García-García L., Eisenach K.D., Murray M., Chaves F.   +18 more
core   +1 more source